Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Research and Markets: Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2012

Research and Markets
Posted on: 12 Oct 12

Research and Markets ( has announced the addition of Global Markets Direct's new report "Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post-polycythemia vera myelofibrosis (PPV-MF), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-polycythemia vera myelofibrosis (PPV-MF). Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


- A snapshot of the global therapeutic scenario for Post-polycythemia vera myelofibrosis (PPV-MF).

- A review of the Post-polycythemia vera myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Post-polycythemia vera myelofibrosis (PPV-MF) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to Buy:

- Identify and understand important and diverse types of therapeutics under development for Post-polycythemia vera myelofibrosis (PPV-MF).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Post-polycythemia vera myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit

Source: Global Markets Direct

Business Wire

Last updated on: 12/10/2012

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.